Pulmonary hypertension in connective tissue diseases, new evidence and challenges

Madelon C. Vonk1 | Els Vandecasteele2 | Arie P. van Dijk3

1Department of the Rheumatic diseases, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
2Department of Cardiology, Gent University, Gent, Belgium
3Department of Cardiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Correspondence
Madelon C. Vonk, rheumatologist Radboud University Nijmegen Medical Centre, huispost 470, Radboudumc, PBox 9101, 6500HB Nijmegen, the Netherlands.
Email: Madelon.Vonk@radboudumc.nl

Abstract
Pulmonary arterial hypertension is a lethal complication of different connective tissue diseases such as systemic sclerosis, mixed connective tissue disease and systemic lupus erythematosus. Although the treatment possibilities for patients with pulmonary arterial hypertension have increased in the last two decades and survival of patients with idiopathic pulmonary arterial hypertension has improved, the latter is not the case for patients with pulmonary arterial hypertension associated with connective tissue disease. In this narrative review, we review recent literature and describe the improvement of early diagnostic possibilities, screening modalities and treatment options. We also point out the pitfalls in diagnosis in this patient category and describe the unmet needs and what the focus of future research should be.

Keywords
connective tissue disease, pulmonary hypertension, systemic lupus erythematosus, systemic sclerosis

1 INTRODUCTION

Pulmonary hypertension (PH) is a progressive disease characterized by an elevated pulmonary arterial pressure and pulmonary vascular resistance. As a consequence of the elevated pulmonary arterial pressure, patients are at risk of right heart failure and death. Patients with connective tissue diseases (CTD) such as systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) may develop PH as a complication of their autoimmune disease. Also in patients suffering from CTDs, the occurrence of PH has a major impact on quality of life and prognosis. In the last years, our knowledge on risk factors, screenings modalities and treatment options has increased and prognosis has improved. In this narrative review, PH in CTD is discussed, with the focus on pulmonary arterial hypertension (PAH), taken up-to-date knowledge on screening, early diagnosis, treatment options and prognosis into account.

2 CLINICAL PRESENTATION AND DIAGNOSIS

Pulmonary hypertension is a severe clinical condition in which loss and obstructive remodelling of the pulmonary vascular bed is responsible for the rise of pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR), resulting in progressive right heart failure and functional decline. Patients with CTD such as SSc, MCTD and SLE are at risk of PH; with PAH being the most progressive form of PH, but also other forms of PH occur and CTD patients...
often suffer from overlap of different forms of PH.\textsuperscript{1} The first signs and symptoms of PAH are generally vague and nonspecific. Patients experience fatigue, dyspnoea on exertion, weakness and light headedness. Those symptoms are often ascribed to the CTD itself or to having a low physical fitness. More severe symptoms such as (near) syncope, angina and/or oedema only occur after extensive pulmonary vasculopathy has developed. The diagnostic approach in patients with a clinical suspicion for PH should include physical examination, laboratory work-up, pulmonary function testing including forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO), echocardiography, high-resolution chest computed tomography scan and ventilation/perfusion lung scanning as the differential diagnosis of PAH should be taken into account.\textsuperscript{3} Blood tests are not useful for the diagnosis of PH but may help distinguish forms of PH and prognosis, such as an elevated N-terminal pro-BNP (NT-pro-BNP) level.\textsuperscript{3} Pulmonary function tests including total lung capacity, FVC and DLCO reveal a mild restrictive component with a marked reduction of DLCO in PAH.\textsuperscript{3} Echocardiography shows a dilated and hypertrophic right ventricle with signs of pressure overload such as systolic septal flattening. Using the regurgitant velocity of tricuspid regurgitation and pulmonary regurgitation and the shape of the velocity curve of the right ventricular outflow tract velocity, systolic, diastolic and mean pulmonary arterial pressures can be estimated. Together with the echocardiographic estimation of right atrial pressure, cardiac index and left atrial pressures, a fairly accurate impression of pulmonary haemodynamics can be obtained.\textsuperscript{4} Ventilation/perfusion lung scanning is the preferred diagnostic tool for chronic embolic disease.\textsuperscript{3} The high-resolution chest computed tomography may show parenchymal lung disease.\textsuperscript{3} The gold standard to diagnose all forms of PH is a right heart catheterization performed as described by the European college of cardiologist guidelines.\textsuperscript{1}

### 3 | CLASSIFICATION

Pulmonary hypertension is diagnosed by right heart catheterization (RHC), revealing a mean pulmonary arterial pressure (PAP) $\geq 25$ mm Hg.\textsuperscript{1,5} With right heart catheterization, PH can be divided into three groups: pre-capillary PH, isolated post-capillary PH (IpcPH) and combined pre- and post-capillary PH (CpcPH) by estimation of the pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR). The characteristics are summarized in Table 1.

Besides this hemodynamic classification, a clinical classification is used. The purpose of clinical classification of PH is to categorize clinical conditions associated with PH based on similar pathophysiological mechanisms, clinical presentation, hemodynamic characteristics and therapeutic management.\textsuperscript{5} The 2018 updated clinical classification of pulmonary hypertension is summarized in Table 2.

Different forms of pulmonary hypertension may occur in patients with connective tissue diseases. The most progressive form of PH, group 1 PAH, occurs as a consequence of remodelling and constriction of the pulmonary arteries and arterioles, leading to a progressive increase of the pulmonary vascular resistance and right heart failure.\textsuperscript{6} It is currently accepted that inflammatory mechanisms contribute to PAH genesis and progression, especially in patients with CTD.\textsuperscript{7,8} Inflammatory cell infiltrates have been detected in plexiform lesions from patients with CTD-associated PAH.\textsuperscript{9} In fact, CTDs are the major cause of PAH, occupying around one-fourth of the total PAH population.\textsuperscript{10} Group 2 PH, which is PH associated with impaired left heart function, may occur as a consequence of CTD as well. As interstitial lung disease is another common complication of CTDs, especially of SSc and MCTD, group 3 PH may also be contributed to CTD. Group 4 PH, due to chronic embolic disease, may be

#### TABLE 1 Hemodynamic definitions of pulmonary hypertension (PH)$^3$

| Definition                           | Characteristics                              | Clinical groups$^a$ |
|-------------------------------------|---------------------------------------------|---------------------|
| Pre-capillary PH                    | mPAP $\geq 25$ mm Hg                        | 1,3,4 and 5         |
|                                     | PAWP $\leq 15$ mm Hg                        |                     |
|                                     | PVR $\geq 3$ WU                             |                     |
| Isolated post-capillary PH (IpcPH)  | mPAP $\geq 25$ mm Hg                        | 2 and 5             |
|                                     | PAWP $> 15$ mm Hg                           |                     |
|                                     | PVR $< 3$ WU                                |                     |
| Combined pre- and post-capillary PH (CpcPH) | mPAP $\geq 25$ mm Hg                        | 2 and 5             |
|                                     | PAWP $> 15$ mm Hg                           |                     |
|                                     | PVR $\geq 3$ WU                             |                     |

Abbreviations: mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; WU, Wood units.

$^a$Group 1: PAH; group 2: PH due to left heart disease; group 3: PH due to lung diseases and/or hypoxia; group 4: due to pulmonary artery obstructions; group 5: PH with unclear and/or multifactorial mechanisms.
associated with CTD as well. Of note is pulmonary veno-occlusive disease which shares the same hemodynamic profile and clinical presentation as other forms of PAH. However, it is associated with a more pronounced venous/capillary involvement and is associated with a poor prognosis, a limited response to PAH therapy and a risk of pulmonary oedema with these treatments. Of note is pulmonary veno-occlusive disease which shares the same hemodynamic profile and clinical presentation as other forms of PAH. However, it is associated with a more pronounced venous/capillary involvement and is associated with a poor prognosis, a limited response to PAH therapy and a risk of pulmonary oedema with these treatments.5,11 This form of PAH occurs especially in SSc. The localization of the different forms of PH is shown in Figure 1.

### 4 | Epidemiology of PAH in Connective Tissue Diseases

Pulmonary arterial hypertension may occur as a complication of various CTDs, such as SSc, MCTD, SLE, primary Sjogren syndrome and (dermat-0-) myositis. Among the CTDs, SSc has the highest known PAH prevalence. PAH affects approximately 8%-12% of patients with SSc and has an incidence of 0.61 cases per 100 patient years.12,13 The prevalence of PAH in non-SSc CTDs remains to be determined due to the lack of large, RHC based cohort studies but is estimated to be lower than in SSc patients.14 Based on a nationwide cohort study in Taiwan and a systematic review of the literature, the prevalence of PAH in SLE is <4%.15,16 For the other CTDs, the prevalence is estimated to be <1%.1

### 5 | Prognosis

The prognosis of patients with certain forms of PH has increased with the availability of several vasoactive drugs, better supportive care, earlier diagnosis and earlier treatment. A number of studies and registries have shown a less favourable outcome of patients with PAH associated with SSc compared to those with idiopathic PAH or non-SSc CTD-associated PAH.17,18 The 3-year survival rate of PAH associated with SSc is estimated to be only 52%, despite the available targeted treatments.19 The survival of SLE-PAH, studied in a nationwide cohort study in France, is better, with 3- and 5-year overall survival rates of 89.4% and 83.9%, respectively.20 In this study, risk factors of death were found to be renal involvement and elevated PVR. In 2 other cohort studies, the presence of anti-U1-RNP antibodies was found to be protective factors for survival.21,22

### 6 | Early Diagnosis of Pulmonary Arterial Hypertension

The symptoms of PAH are nonspecific, especially in CTD patients. Breathlessness, fatigue, weakness, angina and syncope are seen initially during exertion and in advanced cases at rest. Abdominal distension and ankle oedema are signs of progressing right ventricular failure.1

Pulmonary arterial hypertension may occur in both limited cutaneous and diffuse cutaneous SSc, and in patients with a short disease duration and a long disease duration.23 In SSc patients without skin involvement yet (‘early’ SSc), only limited data are available in literature.24 In a Belgian cohort, none of the 84 included SSc patients without skin involvement were diagnosed with PAH.25 Mortality in SSc-PAH is high, and mortality rates are the highest in the

| TABLE 2 | Updated clinical classification of pulmonary hypertension (PH)5 |
|---|---|
| 1 PAH | 1.1 Idiopathic PAH  
1.2 Heritable PAH  
1.3 Drug and toxin-induced PAH  
1.4 PAH associated with:  
1.4.1 Connective tissue disease  
1.4.2 HIV infection  
1.4.3 Portal hypertension  
1.4.4 Congenital heart disease  
1.4.5 Schistosomiasis  
1.5 PAH with long-term responders to calcium channel blockers  
1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement  
1.7 Persistent PH of the newborn syndrome |
| 2 PH due to left heart disease | 2.1 PH due to heart failure with preserved LVEF  
2.2 PH due to heart failure with reduced LVEF  
2.3 Vascular heart disease  
2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH |
| 3 PH due to lung diseases and/or hypoxia | 3.1 Obstructive lung disease  
3.2 Restrictive lung disease  
3.3 Other lung disease with mixed restrictive/obstructive pattern  
3.4 Hypoxia without lung disease  
3.5 Developmental lung disorders |
| 4 PH due to pulmonary artery obstructions | 4.1 Chronic thromboembolic PH  
4.2 Other pulmonary artery obstructions |
| 5 PH with unclear and/or multifactorial mechanism | 5.1 Haematological disorders  
5.2 Systemic and metabolic disorders  
5.3 Others  
5.4 Complex congenital heart disease |

Abbreviations: LVEF, left ventricular ejection fraction; PAH, pulmonary arterial hypertension; PCH, pulmonary capillary haemangiomatosis; PVOD, pulmonary veno-occlusive disease.
SSc patients who are most severely ill (defined by the New York Heart Association functional class [NYHA FC]) at the moment of PAH diagnosis. In a French registry, the 3-year survival rate was 30%-72% in the SSc-PAH patients diagnosed in NYHA FC III/IV whereas the 3-year survival rate was up to 80% when diagnosed in NYHA FC II. However, most of the patients were diagnosed in NYHA FC III/IV and only a minority in NYHA FC II at diagnosis. Systematic screening of SSc patients leads to earlier diagnosis of PAH. Data from a French and an Australian screening programme showed that the SSc patients diagnosed with PAH by screening had lower NYHA FC (≥50% of the included SSc-PAH patients were in NYHA FC I/II at diagnosis, in both cohorts) and lower pulmonary vascular resistance on right heart catheterization as compared to those who were diagnosed by symptoms. Therefore, early diagnosis is key to improve survival in PAH patients. Screening results in earlier diagnosis and thus earlier treatment. International guidelines recommend screening for PAH in SSc patients from 2009 onwards. Evidence has

**FIGURE 1** A schematic view of the pulmonary vasculature. A, aorta; ILD, interstitial lung disease; LAP, left atrial pressure; LV, left ventricle; PAH, pulmonary arterial hypertension; PVOD, pulmonary veno-occlusive disease; RA, right atrium; RV, right ventricle

**FIGURE 2** Echocardiography and pulmonary hypertension. A’, active diastolic velocity of the tricuspid annulus; Ao, aorta; E’, early diastolic velocity of the tricuspid annulus; IVC, inferior vena cava; LA, left atrium; LV, left ventricle; RA: right atrium; RV, right ventricle; RVOT, right ventricular outflow tract; S’, systolic velocity of tricuspid annulus; TRPG, tricuspid regurgitation pressure gradient. Adapted from 51
been accumulating that screening results in improved survival in SSC patients. Different screening methods are used and recommended, based on clinical evaluation, pulmonary function testing, echocardiography, biomarkers or a combination of parameters. For patients with SSC and a disease duration of >3 years and a DLCO α% the DETECT algorithm is used. This DETECT algorithm consists of a 2-step diagnostic algorithm with clinical, laboratory, lung functional and electrocardiographic parameters in step 1 and echocardiography in step 2, resulting in advice to perform a RHC or not. This algorithm has proved to reduce the number of missed diagnoses of PAH in SSC compared to using only echocardiography and symptoms. For all SSC patients, the appropriate screening tools include the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) echocardiographic recommendations (Figure 2), and a combination of a FVC/DLCO > 1.6 and a N-terminal pro-BNP > 2 times upper limit of normal. For high-risk patients (disease duration > 3 years and DLCO < 60% of predicted), the DETECT algorithm can be used as an indicator for referral for RHC. Current guidelines and recommendations also recognize patients along the SSC spectrum such as MCTD, who have other CTDs but with features of SSC, as needing to be screened similar to patients with SSC. In other CTDs, systematic screening for PAH is not recommended given its low prevalence. However, for SLE-associated PAH, several risk factors for PAH have been identified, consisting of longer disease duration of SLE, the presence of interstitial lung disease, the absence of skin rash, the presence of pericardial effusion, the presence of anti-RNP or anti-SSA antibodies, low disease activity, low ESR and elevated uric acid. Careful monitoring of those patients is recommended.

7 | TREATMENT OF PAH

The treatment of PAH in patients with CTDs is a complex strategy based on initial evaluation of severity and prognostic risk, as well as subsequent response to treatment. Patients with PH are to be referred to expert centres and treated by a multidisciplinary team consisting of rheumatologists, cardiologists and chest physicians as well as specialized nurses. As PAH has a severe impact on daily living and is life-threatening, psychological, social and emotional support is advocated which is often provided for by the specialized nurses. General measures for PAH associated with CTD consist of encouragement of physical activity within limits, vaccination against influenza and pneumococcal pneumonia, iron substitution if indicated, the use of diuretics in patients with signs of fluid retention and oxygen when applicable.

The use of high-dose calcium channel blockers (CCB) in CTD-PAH is not recommended. However, the majority of the SSC patients already take CCB for Raynaud’s phenomenon. In contrast to patients suffering from idiopathic PAH, oral anticoagulant therapy is not recommended. According to the ESC/ERS guidelines, in patients with CTD-PAH, the same treatment algorithm as for patients with idiopathic PAH is recommended. Currently approved treatment strategies in PAH target three main pathways: the prostacyclin pathway, the endothelin pathway and the nitric oxide (NO) pathway.

7.1 | Prostacyclin pathway

Prostacyclin analogues bind to the prostacyclin receptor leading to an increase of cyclic adenosine monophosphate (cAMP), resulting in vasodilation, antiproliferative and anti-thrombotic effects. Four agents have been licensed by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for treatment of PAH: epoprostenol (iv), treprostenil (iv, sc, inhaled), iloprost (inhaled) and selexipag, an orally active, selective prostacyclin receptor agonist.

7.2 | Endothelin pathway

Endothelin-1 (ET-1) acts through two receptor subtypes namely ET receptor type A and B. ET-1 causes vasoconstriction and proliferation of the smooth muscle cells by binding to ET type A and B receptor and increases the NO and prostacyclin production by binding to ET type B receptor. Bosentan and macitentan are nonselective ET-1 receptor antagonists (ERA), while ambrisentan is a selective type A ET-1 receptor antagonist.

7.3 | Nitric oxide pathway

Reduced nitric oxide (NO) availability is associated with PAH. NO induces vasodilation and inhibits vascular proliferation by increasing production of cyclic guanosine monophosphate (cGMP). Phosphodiesterases (PDEs) are enzymes that inactivate cGMP. Phosphodiesterase five inhibitors (PDE5-I) (sildenafil and tadalafil) slow the breakdown of cGMP and the soluble guanylate cyclase agonist (riociguat) stimulates cGMP production.

In most of the randomized controlled trials (RCT) on which approval of specific PAH treatment is based, both idiopathic PAH and CTD-PAH patients are included (up to 30% CTD-PAH patients). Focusing on CTD-PAH and SSC-PAH, there are some general remarks and limitations. RCTs
### Table 3: Clinical trials or subgroup analysis of clinical trials on CTD-PAH and SSc-PAH

| Drug       | Reference                  | Type of study Inclusion criteria | Treatment                        | Comp                  |
|------------|----------------------------|----------------------------------|----------------------------------|-----------------------|
|            |                            | RCT, SSc-PAH<sup>a</sup>         | Epoprostenol continuous IV       | Placebo               |
| Prostacyclins |                            | 6MWT > 50 m                      |                                  |                       |
| Epoprostenol | Badesch 2000<sup>52</sup> | NYHA FC II-IV                    |                                  |                       |
|            |                            | Open-label extension of RCT, SSc-PAH<sup>a</sup> |                                  |                       |
|            | Badesch 2009<sup>53</sup> | NYHA FC II-IV                    |                                  |                       |
| Treprostenil | Oudiz 2004<sup>44</sup>   | Subgroup analysis of RCT, CTD-PAH<sup>b</sup> | Treprostenil continuous SC       | Placebo               |
|            |                            | 6MWT 50-450 m                     |                                  |                       |
| Selexipag   | Gaine 2017<sup>39</sup>   | Subgroup analysis of RCT, CTD-PAH<sup>b</sup> | Selexipag po Titration 200-1600 µg 2x/d | Placebo               |
|            |                            | 6MWT 50-450 m                     |                                  |                       |
|            |                            |                                  |                                  |                       |
| ERA        |                            |                                  |                                  |                       |
| Bosentan    | Rubin 2002<sup>55</sup>   | RCT, IPAH/CTD-PAH<sup>b</sup>    | Bosentan po 125-250 mg 2x/d      | Placebo               |
|            | BREATHE-1<sup>55</sup>    | 6MWT 150-450 m                    |                                  |                       |
|            |                            | WHO FC III/IV                     |                                  |                       |
|            | Denton 2006<sup>56</sup>  | Subgroup analysis of an open-label extension of 2 RCTs CTD-PAH<sup>b</sup>, 6MWT 150-500 m, WHO FC III/IV | Bosentan po 125-250 mg 2x/d | Placebo               |
| Macitentan | Pulido 2013<sup>37</sup>  | RCT, IPAH, CTD-PAH, others<sup>b</sup>, 6MWD > 50 m | Macitentan po 10 mg/d | Placebo               |
|            | SERAPHIN<sup>37</sup>     | WHO FC I-IV                       |                                  |                       |
| Ambrisentan | Galie 2008 ARIES-1 and ARIES-2<sup>57</sup> | 2 RCTs IPAH, CTD-PAH, others<sup>b</sup>, 6MWD 150-450 m | Ambrisentan po 5-10 mg/d | Placebo               |
|            |                            | WHO FC I-IV                       |                                  |                       |
| NO pathway | Sildenafil                 | Subgroup analysis of RCT CTD-PAH<sup>b</sup>, 6MWD 100-450 m | Sildenafil po 20-40-80 mg 3x/d | Placebo               |
|            | Badesch 2007<sup>58</sup> | WHO FC II-IV                     |                                  |                       |
| Tadalafil  | Galie 2009<sup>99</sup>   | RCT, IPAH, CTD-PAH, others<sup>b</sup>, 6MWD 150-450 m | Tadalafil po 2.5-10-20-40 mg/d | Placebo               |
|            | PHIRST<sup>99</sup>       | WHO FC I-IV                       |                                  |                       |
| Riociguat   | Ghofrani 2013<sup>60</sup> | RCT, IPAH, CTD-PAH, others<sup>b</sup>, 6MWD 150-450 m | Riociguat po 1.5-2.5 mg 3x/d | Placebo               |
|            | PATENT-1<sup>60</sup>     | WHO FC I-IV                       |                                  |                       |

**Combination therapy**
| N PAH | N IPAH | N CTD (N SSc-PAH) | primary endpoint | Effect in CTD-PAH or SSc-PAH |
|-------|--------|-------------------|------------------|----------------------------|
| 111   | 0      | 111 (111)         | placebo-corrected ∆median 6 MWT at week 12 | SSc 108 m (95%CI: 55.2 to 180 m) |
| 97    | 0      | 97 (97)           | 1-, 2-, 3-year survival | SSc 71%, 52% and 48% |
| 90    | 0      | 90 (45)           | placebo-corrected ∆6MWT at week 12 | CTD 25 m (P = .055) |
| 334   | 0      | 334 (170)         | Combined mortality/morbidity endpoint (median duration of treatment 67 wk) | HR (95%CI) CTD: 0.59 (0.41-0.85) SSc: 0.56 (0.34-0.91) |
| 213   | 150    | 63(47)            | Δ6MWT at week 16 | SSc 43 m (95%CI: NA, P = NS) |
| 66    | 0      | 66 (52)           | placebo-corrected ∆6MWT at week 12-16 | CTD 22.1 m (95%CI: −32 to 76 m) Survival: 85.9% after 1 y and 73.4% after 2 y of bosentan treatment |
| 742   | 404    | 224               | combined mortality/morbidity primary endpoint (median duration of treatment: 115 weeks) | HR (95%CI) CTD: 0.58 (0.33 to 1.02) |
| 201   | 126    | 62                | placebo-corrected ∆6MWT at week 12 | CTD range: 15 to 23 m |
| 192   | 125    | 62                |                               | |
| 84    | 0      | 84 (38)           | Placebo-corrected ∆6MWT at week 12 20 mg, 40 mg or 80 mg | CTD 20 mg: 55 m (95%CI: 24 to 85 m), P < .01, 40 mg: 49 m (95%CI: 19 to 80 m), P < .01, 80 mg: 28 m (95%CI: −14 to 71 m), P = NS |
| 405   | 247    | 95                | Placebo-corrected ∆6MWT at week 16 2.5 mg, 10 mg, 20 mg, 40 mg | CTD 2.5 mg: 18 m (95%CI: −27 to 63 m), 10 mg: 22 m (95% CI: −13 to 56 m), 20 mg: 50 m (95% CI: 16 to 83 m), 40 mg: 49 m (95%CI: 15 to 83 m) |
| 443   | 272    | 111               | Placebo-corrected ∆6MWT at week 12 2.5 mg 3x/d | CTD 27 m (95%CI: −7 to 61 m) |

(Continues)
on treatment of PAH in SSc and CTD are scarce and in the RCTs including both idiopathic PAH and CTD-PAH, subgroup analysis of the CTD-PAH or SSc-PAH subgroup are not always performed or the subgroups were not powered to detect statistical significance. An important evolution in the PAH RCT design is the shifting of the primary endpoint from a short-term correlates such as the six minutes walking test (6MWT) to a long-term true clinical efficacy measure such as time to clinical worsening or a combined mortality/morbidity endpoint. It is known that CTD patients also have many comorbidities such as myositis, arthritis, digital ulcers at the toes and fatigue interfering with the utility of the 6MWT.

Table 3 focuses on the clinical trials or subgroup analyses of clinical trials on treatment of CTD-PAH and SSc-PAH. For the first RCTs and subgroup analyses with

| Drug                  | Reference             | Type of study Inclusion criteria | Treatment                                      | Comp             |
|-----------------------|-----------------------|----------------------------------|------------------------------------------------|------------------|
| Ambrisentan and Tadalafil | Coghlan 2017 AMBITIONb | Subgroup analysis of RCT, CTD-PAHb WHO FC II-III | Combination R/Po ambrisentan 10 mg + tadalafil 40 mg | MonoR/Po ambrisentan 10 mg or Tadalafil 40 mg |

Abbreviations: %, per cent; 6MWT, six-minute walk test; CL, confidence interval; comp, comparator; CTD, connective tissue disease; CTD-PAH or SSc-PAH: ERA, endothelin-1 receptor antagonist; FC, functional class; HR, hazard ratio; IPAH, idiopathic pulmonary arterial hypertension; IV, intravenous; m, metre; mg, milligram; N, number of; NA, not available; NO, nitric oxide; NS, not significant; NYHA, New York Heart Association; others, other causes of PAH than IPAH; PAH, pulmonary arterial hypertension; po, per oral; RCT, randomized controlled trial; SC, subcutaneous; SSc, systemic sclerosis; WHO, World Health Organization; Δ, delta.

*PAH defined as mean pulmonary arterial pressure ≥35 mm Hg.

**PAH defined as mean pulmonary arterial pressure ≥25 mm Hg.

**TABLE 4** Risk assessment in pulmonary arterial hypertension

| Determinants of prognosisa (estimated 1-year mortality) | Low risk < 5% | Intermediate risk 5%-10% | High risk > 10% |
|---------------------------------------------------------|---------------|--------------------------|-----------------|
| Clinical signs of right heart failure                    | Absent        | Absent                   | Present         |
| Progression of symptoms                                  | No            | Slow                     | Rapid           |
| Syncope                                                 | No            | Occasional syncopeb      | Repeated syncopec |
| WHO Functional Class                                     | I-II          | III                      | IV              |
| 6-minute walking distance                                | >440 m        | 165-440 m                | <165 m          |
| Cardiopulmonary exercise test                            | Peak VO₂ > 15 mL/min/kg (>65% predicted) Ve/VCO₂-slope < 36 | Peak VO₂ 11 - 15 mL/min/kg (35%-65% predicted) Ve/VCO₂-slope 36 - 44.9 | Peak VO₂ < 11 mL/min/kg (<35% predicted) Ve/VCO₂-slope ≥ 45 |
| NT-pro-BNP plasma levels                                 | BNP < 50 ng/L | BNP 50-300 ng/L           | NT-pro-BNP > 1400 ng/L |
| NT-pro-BNP < 300 ng/L                                    | NT-pro-BNP 300-1400 ng/L |                             |
| Imaging (echo, CMR)                                      | RA area < 18 cm² | RA area 18-26 cm²        | RA area > 26 cm² |
| Haemodynamics                                            | RAP < 8 mm Hg | RAP 8–14 mm Hg            | RAP > 14 mm Hg  |
|                                                          | CI ≥ 2.5 L/min | CI ≤ 2.0 L/min           | CI ≤ 2.0 L/min  |
|                                                          | SvO₂ ≥ 65%    | SvO₂ 60-65%              | SvO₂ ≤ 60%      |

Abbreviations: 6MWD, 6-minute walking distance; BNP ¼, brain natriuretic peptide; CI, cardiac index; CMR, cardiac magnetic resonance; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; pred., predicted; RA, right atrium; RAP, right atrial pressure; SvO₂, mixed venous oxygen saturation; VE/VCO₂, ventilatory equivalents for carbon dioxide; VO₂, oxygen consumption; WHO, World Health Organization.

*aMost of the proposed variables and cut-off values are based on expert opinion. They may provide prognostic information and may be used to guide therapeutic decisions, but application to individual patients must be done carefully. One must also note that most of these variables have been validated mostly for idiopathic PAH and the cut-off levels used above may not necessarily apply to other forms of PAH. Furthermore, the use of approved therapies and their influence on the variables should be considered in the evaluation of the risk.

*bOccasional syncope during brisk or heavy exercise, or occasional orthostatic syncope in an otherwise stable patient.

*cRepeated episodes of syncope, even with little or regular physical activity. Adapted from the ESC/ERS guidelines on pulmonary hypertension.
6MWT as primary endpoint, lower response rates are seen in CTD-PAH as compared to idiopathic PAH. However, from 2013 onwards, the SERAPHIN, the GRIPHON and the AMBITION trial used a combined mortality/morbidity primary endpoint, consisting of time from the initiation of treatment to the first event (death from any cause, worsening of PAH and need for additional treatment for PAH, lung transplantation or atrial septostomy). In the SERAPHIN and GRIPHON trial, the majority of the patients was already treated with PAH-specific therapy and in the AMBITION trial initial combination therapy was compared to initiation with monotherapy. In the subgroup analyses of CTD-PAH patients in all of these three trials, there was a reduction of combined primary endpoint (Table 3).

Following the international guidelines, in patients with CTD-PAH with NYHA FC II or III, initial oral combination therapy is started (ERA + PDE5-i), while those in NYHA FC IV are treated with initial combination therapy including parenteral prostacyclin (epoprostenol). There is no evidence of a favourable effect of treatment with immunosuppression in SSc-associated PAH. However, treatment with immunosuppressive drugs, consisting of six monthly intravenous pulses of cyclophosphamide and a tapering dosage of prednisolone in SLE and MCTD-associated PAH has resulted in a clinical response in 50% of 16 patients. Furthermore, the French nationwide SLE-PAH study showed a trend towards better survival in patients who received hydroxychloroquine.

8 | TREAT TO TARGET

Risk status for mortality of Idiopathic PAH patients can be assessed by a comprehensive tool described by the ESC and the ERS guidelines. Risk criteria are based on the presence of clinical signs of right heart failure, progression of symptoms, the WHO functional class, the 6MWT, parameters of cardiopulmonary exercise testing, NT-pro-BNP level, presence of right atrial dilatation and pericardial effusion on imaging, and (invasive) haemodynamics. For each criterium, values are set to assign a low, intermediate or high risk of estimated mortality. The average score of the number of low-risk criteria at baseline and during the first follow-up discriminates the risk of death or lung transplantation and enables classification of patients as low (<5%), intermediate (5%-10%) or high risk (>10%) for an estimated 1-year mortality. Several studies investigated the validity of this scoring system by either using noninvasive criteria only or a combination of the noninvasive and invasive criteria. In these studies, it became clear that this scoring system is valid and that the quantification of the number of low-risk criteria present accurately predicts transplant-free survival in PAH (Table 4). Changes in risk from initial evaluation to first follow-up also predict survival. Although PAH associated with CTD is a more progressive disease as idiopathic PAH, this risk stratification tool is valid for PAH-CTD as well. This instrument may help the clinician to intensify treatment by adding a third treatment modality and/or to start parenteral treatment with prostacyclin analogues if indicated. Of note is that lung transplantation is an option for eligible patients with CTDs as well.

9 | UNMET NEEDS

Pulmonary arterial hypertension is a well-known complication in CTDs, particularly in SSc. Ten per cent of the SSc patients will develop PAH during lifetime. However, diagnosing PAH is challenging since SSc patients may have group 1 PAH, group 2 PH secondary to left heart disease (due to myocardial fibrosis), group 3 PH secondary to interstitial lung disease, group 4 PH (CTEPH), pulmonary veno-occlusive disease or a combination as shown in Table 2. Although the number of treatments is increasing also for PAH-CTD, mortality in especially SSc-PAH remains high, with lower survival rates and lower response rate of the PAH-specific therapy as compared to idiopathic PAH.
In CTDs in general, patients suffer from different limitations and morbidity due to their disease and often experience alternating periods of more and less disease activity resulting in fatigue and reduced exercise tolerance. As a result, complaints of constitutional symptoms do not prompt the patients to seek medical help. It is therefore challenging to make an early diagnosis of PH in patients with CTDs. The 6th world symposium on PH task force proposed to change the haemodynamic definition of PH. A mean PAP > 20 mm Hg and PVR ≥ 3 Woods Unit instead of mean PAP ≥ 25 mm Hg. Although patients with borderline PAP (mean PAP 21-24 mm Hg) did not need any PAH-specific treatment, the 2015 ESC/ERS guidelines recommended close monitoring of these patients to detect the possible progression to PH, because of a higher risk of PAH. Many patients with borderline PAP have a mild stage of pulmonary vasculopathy and are at increased risk for developing PH. In SSc, PAH is known as a complication of pulmonary vasculopathy and are at increased risk for developing PH. In the last decade, progression has been made in screening purposes for PAH in SSc, in organization of expert centres for PAH and SSc and in the importance of early start of initial combination therapy.

Another challenging aspect of PAH-CTD is that patients often suffer from a combination of different PH groups such as groups 1, 2 and 3 in one patient, necessitating an even more tailored treatment schedule as in idiopathic PAH patients. However, in clinical trials patients with a combination of causes for PH are excluded and thus treatment of these patients is not evidence based. In our opinion, the main objective for future research should aim to improve prognosis in this vulnerable group by focusing both on morbidity and mortality. Furthermore, translational research on vascular biomarkers and the use of nailfold capillaroscopy could help to define patients at greater risk for the development of PAH and could make personalized screening programmes possible.

CONFLICT OF INTEREST

The authors declare no conflict of interest and no funding for this manuscript.

ORCID

Madelon C. Vonk https://orcid.org/0000-0002-2266-9907

REFERENCES

1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-975.
2. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. The Eur Respir J. 2019;53(1):1-14.
3. Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019;53(1):1-12.
4. Bossone E, D’Andrea A, D’Alto M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr. 2013;26(1):1-14.
5. Simonneau G, Montani D, Celerier JS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1-13.
6. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 2004;43(12):135-145.
7. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12):135-145.
8. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22(2):358-363.
9. Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases.2. Hum Pathol. 2007;38(6):893-902.
10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
11. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2000;162(5):1964-1973.
12. Mukerjee D, Culp B, Gorey D, et al. Prevalence and outcome in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Rheum. 2000;162(5):1964-1973.
13. Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60(6):1831-1839.
14. Kato M, Atsumi T. Pulmonary arterial hypertension associated with connective tissue diseases: a review focusing on distinctive clinical aspects. Eur J Clin Invest. 2018;48(2):e12876.
15. Yang X, Mardekian J, Sanders KN, Mychaskiw MA, Thomas J. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol. 2013;32(10):1519-1531.
16. Chen H-A, Hsu T-C, Yang S-C, et al. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Res Ther. 2019;21(1):82.
17. Hurley J, Condiffe R, Elliot CA, et al. ASPIRE registry: assessing the Spectrum of Pulmonary Hypertension Identified at a Referred centre. Eur Respir J. 2012;39(4):945-955.
18. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72(12):1940-1946.
19. LeFevre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412-2423.
20. Hachulla E, Jais X, Cinquetti G, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French pulmonary hypertension registry. *Chest*. 2018;153(1):143-151.

21. Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. *Medicine (Baltimore)*. 2016;95(10):e2761.

22. Sobanski V, Giovannelli J, Lynch BM, et al. Characteristics and survival of Anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. *Arthritis Rheumatol*. 2016;68(2):484-493.

23. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? *Chest*. 2009;136(5):1211-1219.

24. Leroy EC, Medsger TA. Criteria for the classification of early Systemic Sclerosis. *J Rheumatol*. 2001;28(7):1573-1576.

25. Vandecasteele E, Mensels K, Thevissen K, et al. Prevalence and incidence of pulmonary arterial hypertension: 10-year follow-up of an unselected systemic sclerosis cohort. *J Scleroderma Relat*. 2017;2(3):196-202.

26. Hachulla E, Launay D, Yaici A, et al. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. *Rheumatology (Oxford)*. 2010;49(5):940-944.

27. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. *Arthritis Rheum*. 2011;63(11):3522-3530.

28. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. *Intern Med J*. 2009;39(10):682-691.

29. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol*. 2009;53(17):1573-1619.

30. Khanna D, Gladue H, Channick R, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. *Arthritis Rheum*. 2013;65(12):3194-3201.

31. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheum Dis*. 2014;73(7):1340-1349.

32. Young A, Nagaraja V, Basiliou M, et al. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. *Semin Arthritis Rheum*. 2019;48(6):1059-1067.

33. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016;37(1):67-119.

34. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Resp J*. 2019;53(1):1801889.

35. Guillemin L, Armstrong I, Aldrighetti R, et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. *Eur Resp Rev*. 2013;22(130):535-542.

36. Meier FMP, Frommer KW, Dinsé R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. *Ann Rheum Dis*. 2012;71(8):1355-1360.

37. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. *N Engl J Med*. 2013;369(9):809-818.

38. Coghlan JG, Galiè N, Barberà JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. *Ann Rheum Dis*. 2017;76(7):1219-1227.

39. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. *Eur Resp J*. 2017;50(2):1602493.

40. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension. *Arthritis Rheum*. 2008;58(2):521-531.

41. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *Eur Resp J*. 2017;50(2):1700889.

42. Hoepera MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. *Eur Resp J*. 2017;50(2):1700740.

43. Kylhammer D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. *Eur Heart J*. 2018;39(47):4175-4181.

44. Boucly A, Cotin T, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. *Eur Resp J*. 2017;50(4):1700465.

45. Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. *Ann Transplant*. 2000;5(3):38-43.

46. Vandecasteele EH, De Pauw M, Brussels G, et al. The heart and pulmonary arterial hypertension in systemic sclerosis. *Acta Clin Belg*. 2016;71(1):1-18.

47. Valério CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. *Arthritis Rheum*. 2013;65(4):1074-1084.

48. Visovatti SH, Distler O, Coghlan JG, et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. *Arthritis Res Ther*. 2014;16(6):493.

49. Hoffmann-Vold A-M, Fretheim H, Midtvedt Ø, et al. Frequencies of sarcoidosis-associated pulmonary hypertension. *Eur Resp J*. 2018;53(2):4175-4181.

50. Bae S, Sagar R, Bolster MB, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. *Ann Rheum Dis*. 2012;71(8):1335-1342.

51. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism development Toed in collaboration with the European Respiratory Society (ERS). *Eur Heart J*. 2020;41(4):543-603.
scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-434.

53. Badesch DB, McGoon MD, Barst RJ, et al. Long-term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009;36(10):2244-2249.

54. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126(2):420-427.

55. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903.

56. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65(10):1336-1340.

57. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-3019.

58. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417-2422.

59. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894-2903.

60. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-340.

How to cite this article: Vonk MC, Vandecasteele E, van Dijk AP. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. Eur J Clin Invest. 2020;51:e13453. https://doi.org/10.1111/ect.13453